Treatment of Splenic Marginal Zone Lymphoma in Concomitant Chronic Hepatitis C Virus (HCV) Infection

Splenic marginal zone lymphoma (SMZL) occurring alongside a concomitant chronic hepatitis C virus (HCV) infection represents a distinct clinical situation that requires a tailored management approach. The co-existing viral infection is a primary consideration in determining how this lymphoma is treated.

This protocol applies to patients diagnosed with SMZL who also have a concomitant chronic HCV infection. In this subgroup, anti-HCV therapy is specifically indicated as a treatment consideration — particularly in patients who do not immediately require conventional lymphoma treatment. The viral infection is not a background finding; it directly shapes the therapeutic strategy.

The protocol centres on antiviral (anti-HCV) therapy. The specific regimen, sequencing, conditions for initiation, and the complete algorithm are detailed in the structured evidence-based protocol — access it below.